Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Lawitz

Showing results (11-20 of 157) with videos related to

Pageof 16
Sort By:
Expert Opinion on Investigational Drugs|September 15, 2019
GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)Naim Alkhouri, Eric Lawitz, Mazen Noureddin, et al.
Clinical and Molecular Hepatology|August 4, 2025
Prospects of Late-Stage Development Agents in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)Brian Lee, Ussama Ghumman, Lisa D Pedicone, et al.
Clinical Pharmacology in Drug Development|November 1, 2023
Pharmacokinetics and Safety Evaluation of Single-Dose Saroglitazar Magnesium in Subjects with Hepatic ImpairmentEric Lawitz, Deven Parmar, Taufik Momin, et al.
Clinical Case Reports|April 12, 2017
An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirinFred Poordad, Eric Lawitz, Julio A Gutierrez, et al.
Clinical Pharmacokinetics|January 26, 2026
Pharmacokinetics and Safety of a Single Dose of Brensocatib in Participants with Hepatic Impairment and Matched Participants with Normal Hepatic FunctionsHelen Usansky, Sam Au Yeung, Sherry Li, et al.
Current Medical Research and Opinion|December 9, 2025
Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutideHusam Albarmawi, Firas Dabbous, Abdalla Aly, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 15, 2009
Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label studyDaniel E Brady, Dawn M Torres, Jong W An, et al.
Antiviral Therapy|January 28, 2014
Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938Jeremie Guedj, Phillip S Pang, Jill Denning, et al.
Journal of Hepatology|May 20, 2008
Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patientsEric Lawitz, Maribel Rodriguez-Torres, Andrew J Muir, et al.
Antimicrobial Agents and Chemotherapy|December 25, 2012
Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infectionEric Lawitz, Maribel Rodriguez-Torres, Jill M Denning, et al.
Pageof 16

Showing results (11-20 of 157) with videos related to

Sort By:
Pageof 16
Expert Opinion on Investigational Drugs|September 15, 2019
GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)Naim Alkhouri, Eric Lawitz, Mazen Noureddin, et al.
Clinical and Molecular Hepatology|August 4, 2025
Prospects of Late-Stage Development Agents in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)Brian Lee, Ussama Ghumman, Lisa D Pedicone, et al.
Clinical Pharmacology in Drug Development|November 1, 2023
Pharmacokinetics and Safety Evaluation of Single-Dose Saroglitazar Magnesium in Subjects with Hepatic ImpairmentEric Lawitz, Deven Parmar, Taufik Momin, et al.
Clinical Case Reports|April 12, 2017
An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirinFred Poordad, Eric Lawitz, Julio A Gutierrez, et al.
Clinical Pharmacokinetics|January 26, 2026
Pharmacokinetics and Safety of a Single Dose of Brensocatib in Participants with Hepatic Impairment and Matched Participants with Normal Hepatic FunctionsHelen Usansky, Sam Au Yeung, Sherry Li, et al.
Current Medical Research and Opinion|December 9, 2025
Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutideHusam Albarmawi, Firas Dabbous, Abdalla Aly, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 15, 2009
Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label studyDaniel E Brady, Dawn M Torres, Jong W An, et al.
Antiviral Therapy|January 28, 2014
Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938Jeremie Guedj, Phillip S Pang, Jill Denning, et al.
Journal of Hepatology|May 20, 2008
Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patientsEric Lawitz, Maribel Rodriguez-Torres, Andrew J Muir, et al.
Antimicrobial Agents and Chemotherapy|December 25, 2012
Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infectionEric Lawitz, Maribel Rodriguez-Torres, Jill M Denning, et al.
Pageof 16